Overview
flowchart TD
clinical_trials_peripheral_bio["Peripheral Biomarkers in Neurodegenerative Demen"]
style clinical_trials_peripheral_bio fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_peri_0["Study Details"]
clinical_trials_peripheral_bio -->|"includes"| clinical_trials_peri_0
style clinical_trials_peri_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_peri_1["Scientific Background"]
clinical_trials_peripheral_bio -->|"includes"| clinical_trials_peri_1
style clinical_trials_peri_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_peri_2["The Challenge of Differential Diagnosis"]
clinical_trials_peripheral_bio -->|"includes"| clinical_trials_peri_2
style clinical_trials_peri_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_peri_3["Advantages of Peripheral Biomarkers"]
clinical_trials_peripheral_bio -->|"includes"| clinical_trials_peri_3
style clinical_trials_peri_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_peri_4["Biomarker Targets"]
clinical_trials_peripheral_bio -->|"includes"| clinical_trials_peri_4
style clinical_trials_peri_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_peri_5["Neurofilament Light Chain NfL"]
clinical_trials_peripheral_bio -->|"includes"| clinical_trials_peri_5
style clinical_trials_peri_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
This study aims to improve diagnostic accuracy and prognostic confidence in neurodegenerative diseases causing dementia, including Progressive Supranuclear Palsy (PSP), Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), Parkinson's Disease (PD), and Dementia with Lewy Bodies (DLB). The study utilizes peripheral blood biomarkers to address one of the most significant challenges in neurodegenerative disease management: accurate and early diagnosis.
Differentiating between neurodegenerative diseases can be challenging due to substantial clinical overlap between syndromes, variable presentation within disorders, and the need for objective biomarkers to guide diagnosis and treatment decisions.
Study Details
NCT Number : NCT06529744Status : RecruitingStudy Type : Observational (Biorepository)Conditions : PSP, Alzheimer's Disease, FTD, Parkinson's Disease, Dementia with Lewy BodiesEnrollment : OngoingSites : Multiple centersScientific Background
The Challenge of Differential Diagnosis Neurodegenerative diseases share common clinical features:
Cognitive impairment
Motor symptoms
Behavioral changes
Progressive decline
However, the underlying pathologies differ substantially:
Tauopathies : PSP, Corticobasal Syndrome (CBS), Alzheimer's DiseaseSynucleinopathies : Parkinson's Disease, Dementia with Lewy Bodies, Multiple System AtrophyTDP-43 proteinopathies : Most forms of Frontotemporal DementiaAccurate diagnosis is critical for:
Prognostic counseling
Clinical trial enrollment
Therapeutic decision-making
Genetic counseling
Advantages of Peripheral Biomarkers Peripheral blood biomarkers offer significant advantages over CSF and imaging biomarkers:
Accessibility
Blood collection is minimally invasive
Can be performed in routine clinical settings
Enables longitudinal monitoring
Cost-effectiveness
Lower than neuroimaging or CSF analysis
Scalable for large populations
Practicality
No special equipment required
Samples can be processed locally
Suitable for remote and underserved areas
Biomarker Targets
Neurofilament Light Chain (NfL) NfL is a promising axonal damage marker:
Elevated in serum and CSF across multiple neurodegenerative conditions
Correlates with disease severity and progression
Higher levels generally indicate more aggressive disease
Particularly elevated in PSP compared to PD
Tau Protein Tau isoforms provide disease-specific information:
Total tau (t-tau) : General neuronal damagePhosphorylated tau (p-tau) : Specific to AD pathology4R tau : Elevated in PSP and CBSTau PET imaging correlates with blood tau levels
Alpha-Synuclein Key marker for synucleinopathies:
Total alpha-synuclein : Elevated in PD, DLBOligomeric alpha-synuclein : More disease-specific than totalSeed amplification assays (RT-QuIC) detect pathological forms
Emerging as diagnostic tool for DLB and PD
Neurogranin Synaptic damage marker:
Specific to AD compared to other dementias
Correlates with cognitive decline
More sensitive than tau for synaptic dysfunction
Inflammatory Markers The peripheral immune response reflects CNS pathology:
Cytokine profiles differentiate disease types[@strauss2025]
Microglial activation markers
Peripheral monocyte alterations
Study Objectives
Primary Objectives
Identify peripheral blood biomarkers that distinguish between neurodegenerative disease subtypes
Develop diagnostic algorithms combining multiple biomarkers
Establish reference ranges for clinical use
Secondary Objectives
Improve prognostic accuracy
Enable earlier diagnosis
Correlate biomarkers with clinical severity
Validate biomarkers against neuroimaging and CSF
Clinical Correlation
Standardized Diagnostic Criteria
NINDS-SPSP criteria for PSP
NIA-AA criteria for Alzheimer's disease
Movement Disorder Society criteria for Parkinson's disease
Consensus criteria for FTD and DLB
Clinical Rating Scales
MMSE and MoCA for cognition
UPDRS for parkinsonism
PSP Rating Scale
CDR for dementia staging
FBI (Frontal Behavioral Inventory)
Neuroimaging
MRI for atrophy patterns
Tau PET (Flortaucipir)
Dopamine transporter SPECT
Longitudinal Follow-up
Annual assessments
Tracking disease progression
Correlation with biomarker changes
Eligibility Criteria
Inclusion Criteria
Suspected or confirmed neurodegenerative dementia
Age 50-90 years
Willingness to donate blood samples
Capacity to provide informed consent
Availability for longitudinal participation
Exclusion Criteria
Active inflammatory or autoimmune disease
Recent infection (within 4 weeks)
Cancer within 5 years
Significant psychiatric disease
Substance abuse
Biomarker Development Pipeline
Phase 1: Discovery
Untargeted proteomics
Metabolomics
Transcriptomics
Phase 2: Validation
Targeted assays for promising candidates
Cross-platform validation
Multi-cohort replication
Phase 3: Clinical Implementation
Assay standardization
Clinical cutoff development
Regulatory approval
Emerging Biomarker Technologies
Seed Amplification Assays
RT-QuIC and PMCA Real-Time Quaking-Induced Conversion (RT-QuIC) and Protein Misfolding Cyclic Amplification (PMCA) enable detection of pathological proteins:
Alpha-synuclein RT-QuIC : Detects misfolded α-synuclein in CSF with >90% sensitivity for PD and DLBTau RT-QuIC : Identifies pathological tau aggregates in CSFTDP-43 RT-QuIC : Detects TDP-43 pathology in FTD and ALSAdvantages over Traditional Assays
Higher sensitivity : Detects early-stage diseaseDisease specificity : Distinguishes between proteinopathiesQuantitative potential : Correlates with disease severity
Multi-Marker Panels Combining multiple biomarkers improves diagnostic accuracy:
Panel Example for Differential Diagnosis | Biomarker | AD | PD | PSP | CBS |
Single-Cell Analysis Emerging technologies enable cell-type specific biomarker discovery:
Single-cell RNA sequencing : Identifying disease-specific transcriptional signaturesProteomics at single-cell resolution : Cell-type specific protein expressionFlow cytometry : Peripheral immune cell phenotypingTechnical Considerations
Pre-analytical Variables Proper sample handling is critical for biomarker accuracy:
| Variable | Impact | Mitigation |
Assay Standardization
Challenges
Different assay platforms produce varying results
Lack of reference materials for many biomarkers
Inter-laboratory variability
Solutions
Development of certified reference materials
International standardization initiatives
Centralized core laboratory testing
Future Directions
Point-of-Care Testing Emerging technologies enable bedside biomarker assessment:
Lateral flow assays : Rapid, low-cost detectionMicrofluidic devices : Integrated sample-to-answer systemsElectrochemical sensors : Wearable biomarker monitoringArtificial Intelligence Integration Machine learning approaches will:
Combine multiple biomarkers for diagnostic prediction
Identify novel biomarker combinations
Enable personalized risk stratification
Predict treatment response
Clinical Significance Peripheral biomarker implementation could transform neurodegenerative disease care:
Diagnostic Accuracy
Reduce diagnostic uncertainty
Enable early intervention
Guide specialist referral
Clinical Trial Enrichment
Biomarker-defined populations
Enrichment strategies
Surrogate endpoints
Disease Monitoring
Track progression objectively
Assess treatment response
Personalize care
Healthcare Delivery
Remote monitoring
Telehealth integration
Population screening
See Also
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)
[Tau Protein](/proteins/tau)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Biomarkers](/biomarkers)
External Links
[ClinicalTrials.gov: NCT06529744](https://clinicaltrials.gov/study/NCT06529744)
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.-ucla.edu/)
[Michael J. Fox Foundation Biomarker Research](https://www.michaeljfox.org/)
References
[Strauss et al., Peripheral innate immunophenotype in neurodegenerative disease: blood-based profiles and links to survival (2025)](https://pubmed.ncbi.nlm.nih.gov/39472664/)
[Hansson O, et al. Blood-based biomarkers for neurodegenerative diseases. Nature Reviews Neurology. 2024](https://pubmed.ncbi.nlm.nih.gov/)
[Zetterberg H, et al. Neurofilament light chain in cerebrospinal fluid and blood. Clinical Chemistry. 2023](https://pubmed.ncbi.nlm.nih.gov/)
[Blennow K, et al. A review of fluid biomarkers for Alzheimer's disease. Nature Reviews Neurology. 2023](https://pubmed.ncbi.nlm.nih.gov/)
[Poewe W, et al. Biomarkers in Parkinson's disease: Current status and future directions. Movement Disorders. 2024](https://pubmed.ncbi.nlm.nih.gov/)
[Boxer AL, et al. Frontotemporal dementia biomarkers: Current status and future directions. Alzheimer's & Dementia. 2024](https://pubmed.ncbi.nlm.nih.gov/) Show full description